

Validation Ranges

Recipient Baseline Data (Form 2000)		
Question Number	Description	Validation Range
141	AST (SGOT)	0-200 U/L or 0-3.2 μ kat/L
144	Total serum bilirubin	0.2-15 mg/dL or 3.5-263 μ mol/L
146	Upper limit of normal for your institution - bilirubin	0.2-2.5 mg/dL or 3.5-43.9 μ mol/L
147	LDH	30-1400 U/L or 526.3-24,561.4 μ kat/L
149	Upper limit of normal for your institution - LDH	100-1250 U/L or 1,754.4-21,929.8 μ kat/L
150	Serum creatinine	0.1-4 mg/dL or 8.8-353.9 μ mol/L or 0.0088-0.3539 mmol/L
152	Upper limit of normal for your institution – creatinine	0.1-4 mg/dl or 8.8495-353.9822 μ mol/L or 0.0088-0.3539 mmol/L
154	WBC	3.2-9.8 $\times 10^9$ /L or 3,200-9,800 $\times 10^6$ /L
161	Platelets	130-1400 $\times 10^9$ /L or 130,000-400,000 $\times 10^6$ /L
184	Height at initiation of pre-HSCT prep	12-80 in or 30-203 cm
185	Actual weight at initiation of pre-HSCT prep.	1-440 lbs or 1-200 kg
186	Dosing body weight used for pre-HSCT prep.	1-440 lbs or 1-200 kg
193	Total dose TBI	1-16 Gy or 100-1600 cGy
196	Dose per fraction TBI	0.1-3.5 Gy or 10-350 cGy
197	Number of days TBI	2-6
198	Total number of fractions	2-12
199	Total dose lymphoid or nodal regions	1-16 Gy or 100-1600 cGy
202	Dose per fraction lymphoid or nodal regions	0.1-2.5 Gy or 10-250 cGy
203	Number of days lymphoid or nodal regions	2-6
204	Total number of fractions lymphoid or nodal regions	2-12
205	Total dose thoraco-abdominal region.	1-16 Gy or 100-1600 cGy
208	Dose per fraction thoraco-abdominal region	0.1-2.5 Gy or 10-250 cGy
209	Number of Days thoraco-abdominal region	2-6
210	Total number of fractions thoraco-abdominal region	2-12
213	Total dose - CNS	1-18 Gy or 100-1,800 cGy
216	Total dose - Gonadal	1-5 Gy or 100-500 cGy
219	Total dose - Splenic	1-15 Gy or 100-1,500 cGy
222	Total dose - Site of residual tumor	1-16 Gy or 100-1600 cGy
226	Total dose - Other site	1-18 Gy or 100-1,800 cGy
231	Total dose - ALG, ALS, ATG, ATS	0-15,000
256	Total dose - Busulfan	0-2,000
270	Total dose - Methylprednisolone	0-10,000
274	Total dose - Prednisone	0-300

(cont.)

Validation Ranges (continued)

Recipient Baseline Data (Form 2000 - continued)		
Question Number	Description	Validation Range
280	Total dose - Other corticosteroid	0-10,000
284	Total dose - Cyclophosphamide	0-24,000
287	Total dose - Cytarabine (Ara-C)	0-90,000
290	Total dose - Etoposide (VP-16)	0-7,500
306	Total dose - Intrathecal methotrexate	0-25,000
316	Total dose - Melphalan (L-Pam)	0-300
361	Total dose - Thiotepa	0-1,250
364	Total dose - Other drug	0-25,000
375	Specify the number of prior HSCTs	0-14
100 Days Post-HSCT Data (Form 2100)		
38	WBC first day of decline	0.1-2 x10 ⁹ /L or 100-2,000 x10 ⁶ /L
42	WBC actual day of recovery	0.5-11 x10 ⁹ /L or 500-11,000 x10 ⁶ /L
43	Neutrophils actual day of recovery	0-99
49	WBC current findings	0.1-200 x10 ⁹ /L or 100-200,000 x10 ⁶ /L
50	Neutrophils current findings	0-99.9
51	Lymphocytes current findings	0-99.9
52	Hemoglobin current findings	0.5-18 g/dL or 0-0.18 g/L or 3.10-11.17 mmol/L
53	Hematocrit current findings	15-55
54	Platelets current findings	5-800 x10 ⁹ /L or 5,000-800,000 x10 ⁶ /L
55	IgG	100-2,000 mg/dL or 10-200 g/dL or 1-20 g/L
57	IgM	0-300 mg/dL or 0-30 g/dL or 0-3 g/L
59	IgA	0-400 mg/dL or 0-40 g/dL or 0-4 g/L
72	CD3	0-2,500 x10 ⁹ /L or 0-2,500,000 x10 ⁶ /L
73	CD4	0-1,500 x10 ⁹ /L or 0-1,500,000 x10 ⁶ /L
74	CD8	0-1,000 x10 ⁹ /L or 0-1,000,000 x10 ⁶ /L
75	CD20	0-2,000 x10 ⁹ /L or 0-2,000,000 x10 ⁶ /L
76	CD56	0-1,000 x10 ⁹ /L or 0-1,000,000 x10 ⁶ /L
87	Percent donor cells, quantitative method	0-100
88	Percent host cells, quantitative method	0-100
169	Percent donor cells, quantitative method	0-100
170	Percent host cells, quantitative method	0-100
290	Platelet count at diagnosis of Chronic GVHD	5-500 x10 ⁹ /L or 5,000-500,000 x10 ⁶ /L
481	Maximum bilirubin in first 100 days	0.1-40
571	Total number of inpatient days in first 100 days post HSCT	1-100
582	Number of cell infusions given within 10 weeks of the first DCI	0-28
606	Specify number of units	0-999

(cont.)

Validation Ranges (continued)

100 Days Post-HSCT Data (Form 2100 - continued)		
Question Number	Description	Validation Range
610	Number of leukaphereses	0-99
619	CD3+ cells	0-99 x10 ⁹ /L or 0-9999.99 x10 ⁶ /L
620	CD4+ cells	0-99 x10 ⁹ /L or 0-9999.99 x10 ⁶ /L
621	CD8+ cells	0-99 x10 ⁹ /L or 0-9999.99 x10 ⁶ /L
622	CD34+ cells	0-99 x10 ⁹ /L or 0-9999.99 x10 ⁶ /L
623	NK cells	0-99 x10 ⁹ /L or 0-9999.99 x10 ⁶ /L
624	Nucleated cells	0-99 x10 ⁹ /L or 0-9999.99 x10 ⁶ /L
625	Mesenchymal cells	0-99 x10 ⁹ /L or 0-9999.99 x10 ⁶ /L
Six Months to Two Years Post-HSCT Data (Form 2200)		
9	WBC	0.1-2 x10 ⁹ /L or 100-2,000 x10 ⁶ /L
10	Neutrophils	0-99
13	WBC	0.5-11 x10 ⁹ /L or 500-11,000 x10 ⁶ /L
14	Neutrophils	0-99
20	WBC	0.1-200 x10 ⁹ /L or 100-200,000 x10 ⁶ /L
21	Neutrophils	0-99.9
22	Lymphocytes	0-99.9
23	Hemoglobin	0.5-18 g/dL or 0-0.18 g/L or 3.10-11.17 mmol/L
24	Hematocrit	15-55
25	Platelets	5-800 x10 ⁹ /L or 5,000-800,000 x10 ⁶ /L
26	IgG	100-2,000 mg/dL or 10-200 g/dL or 1-20 g/L
28	IgM	0-300 mg/dL or 0-30 g/dL or 0-3 g/L
30	IgA	0-400 mg/dL or 0-40 g/dL or 0-4 g/L
43	CD3	0-2,500 x10 ⁹ /L or 0-2,500,000 x10 ⁶ /L
44	CD4	0-1,500 x10 ⁹ /L or 0-1,500,000 x10 ⁶ /L
45	CD8	0-1,000 x10 ⁹ /L or 0-1,000,000 x10 ⁶ /L
46	CD20	0-2,000 x10 ⁹ /L or 0-2,000,000 x10 ⁶ /L
47	CD56	0-1,000 x10 ⁹ /L or 0-1,000,000 x10 ⁶ /L
58	Percent donor cells, quantitative method	0-100
59	Percent host cells, quantitative method	0-100
140	Percent donor cells, quantitative method	0-100
141	Percent host cells, quantitative method	0-100
231	Platelet count at diagnosis of chronic GVHD	5-500 x10 ⁹ /L or 5,000-500,000 x10 ⁶ /L
421	Maximum bilirubin since last report	0.1-40
523	Specify the number of cell infusions given within 28 days of the first DCI	0-28
547	Specify number of units	0-999
551	Number of leukaphereses	0-99
560	CD3+ cells	0-99 x10 ⁹ /L or 0-9999.99 x10 ⁶ /L

(cont.)

Validation Ranges (continued)

Six Months to Two Years Post-HSCT Data (Form 2200 - continued)		
Question Number	Description	Validation Range
561	CD4+ cells	0-99 x10 ⁹ /L or 0-9999.99 x10 ⁶ /L
562	CD8+ cells	0-99 x10 ⁹ /L or 0-9999.99 x10 ⁶ /L
563	CD34+ cells	0-99 x10 ⁹ /L or 0-9999.99 x10 ⁶ /L
564	NK cells	0-99 x10 ⁹ /L or 0-9999.99 x10 ⁶ /L
565	Nucleated cells	0-99 x10 ⁹ /L or 0-9999.99 x10 ⁶ /L
566	Mesenchymal cells	0-99 x10 ⁹ /L or 0-9999.99 x10 ⁶ /L
Yearly Follow-up for Greater Than Two Years Post-HSCT Data (Form 2300)		
63	Platelet count at diagnosis of chronic GVHD	5-500 x10 ⁹ /L or 5,000-500,00 x10 ⁶ /L
222	Specify the number of cell infusions given within 28 days of the first DCI	0-28
246	Specify number of units	0-999
250	Number of leukaphereses	0-99
259	CD3+ cells	0-99 x10 ⁹ /L or 0-9999.99 x10 ⁶ /L
260	CD4+ cells	0-99 x10 ⁹ /L or 0-9999.99 x10 ⁶ /L
261	CD8+ cells	0-99 x10 ⁹ /L or 0-9999.99 x10 ⁶ /L
262	CD34+ cells	0-99 x10 ⁹ /L or 0-9999.99 x10 ⁶ /L
263	NK cells	0-99 x10 ⁹ /L or 0-9999.99 x10 ⁶ /L
264	Nucleated cells	0-99 x10 ⁹ /L or 0-9999.99 x10 ⁶ /L
265	Mesenchymal cells	0-99 x10 ⁹ /L or 0-9999.99 x10 ⁶ /L
Pre-HSCT Disease Forms		
Acute Lymphoblastic Leukemia (AML) Pre-HSCT Data (Form 2011)		
121	WBC	1-500
122	Blasts in blood	0-100
123	Blasts in bone marrow	0-100
Myelodysplasia/Myeloproliferative Disorders (MDS/MPS) Pre-HSCT Data (Form 2014)		
18	WBC	0.1-200 x10 ⁹ /L or 100-200,000 x10 ⁶ /L
19	Hemoglobin	5-18 g/dL or 0.05-0.18 g/L or >3.10-11.17 mmol/L
21	Platelets	10-1,500 x10 ⁹ /L or 10,000-1,500,000 x10 ⁶ /L
23	Neutrophils	0-99
24	Monocytes	0-99
25	Blasts in blood	0-> 30
29	Blasts in marrow	0-29
187	Monocytes in blood	0-99
188	Blasts in blood	0-99
193	Blasts in marrow	0-100

(cont.)

Validation Range (continued)

Hodgkin and Non-Hodgkin Lymphoma (HL/NHL) Pre-HSCT Data (Form 2018)		
Question	Description	Validation Range
27	LDH at diagnosis	30-1400 U/L or 526.3- 24,561.4 μ kat/L
28	Upper limit of normal for LDH	100-1250 U/L or 1754.4- 21,929.8 μ kat/L
133	Specify the size of the largest nodal mass	0-20
Neuroblastoma (NEU) Pre-HSCT Data (Form 2026)		
3	Number of tumors present - adrenal gland	1-< 99
5	Number of tumors present - bone	1-< 99
7	Number of tumors present - bone marrow	1-< 99
9	Number of tumors present - cerebellum	1-< 99
11	Number of tumors present - CSF	1-< 99
13	Number of tumors present - cerebrum	1-< 99
15	Number of tumors present - cranial nerves	1-< 99
17	Number of tumors present - liver	1-< 99
19	Number of tumors present - lymph nodes	1-< 99
21	Number of tumors present - mediastinum	1-< 99
23	Number of tumors present - paraspinal ganglion	1-< 99
25	Number of tumors present - retro-orbital area	1-< 99
27	Number of tumors present - skin	1-< 99
29	Number of tumors present - other	1-< 99
95	Number of metaphases	> 1-< 100
111	Specify the number of sisters affected	1-< 99
113	Specify the number of brothers affected	1-< 99
Aplastic Anemia (APL) Pre-HSCT Data (Form 2028)		
19	WBC	0.1-10
20	Hemoglobin	2-10
22	Platelets	10-200
25	Reticulocytes	0-23
Fanconi Anemia/Constitutional Anemia (FA/CA) Pre-HSCT Data (Form 2029)		
40	Blasts in marrow	0-2
96	Exon mutation	1-99
98	Intron mutation	1-99
110	Total number of cells studied	1-99
111	Number of aberrations per cell	1-999
112	Number of cells with no aberrations	1-99
114	Total number of cells studied	1-99
115	Number of aberrations per cell	1-999
116	Number of cells with no aberrations	1-99
131	Total number of cells studied	1-99
132	Number of aberrations per cell	1-999

(cont.)

Validation Range (continued)

Fanconi Anemia/Constitutional Anemia (FA/CA) Pre-HSCT Data (Form 2029)		
Question	Description	Validation Range
133	Number of cells with no aberrations	1-99
135	Total number of cells studied	1-99
136	Number of aberrations per cell	1-999
137	Number of cells with no aberrations	1-99
X-Linked Lymphoproliferative Syndrome (XLP) Pre-HSCT Data (Form 2034)		
28	Radiation therapy total dose	200-6000 cGY
Leukodystrophies (LDS) Pre-HSCT Data (Form 2037)		
5	Galactocerebrosidase enzyme activity - donor	0-1000
10	Mean fasting plasma very-long-chain fatty acid (VLCFA) C26:0 level at diagnosis	0.51-2.0
13	Plasma level	0.13-2
27	Opening pressure	0-70
46	Full scale score	40-160
47	Performance score	40-160
48	Verbal score	40-160
51	Communication skills	40-160
52	Daily living skills	40-160
53	Socialization skills	40-160
57	Visual acuity of right eye	10-500
58	Visual acuity of left eye	10-500
59	Visual acuity of both eyes	20-20 or 10-500
Mucopolysaccharidosis and Other Storage Diseases (MUC) Pre-HSCT Data (Form 2038)		
19	Opening pressure	> 5-70
34	Full scale score	40-160
35	Verbal score	40-160
36	Performance score	40-160
39	Communication skills	40-160
40	Daily living skills	40-160
41	Socialization skills	40-160
58	Oxygen saturation on room air	80-100
69	Ejection fraction	0-100
70	Shortening fraction	15-50
Systemic Sclerosis (SSC) Pre-HSCT Data (Form 2044)		
92	Total modified Rodnan Skin Score	≤ 51
152	Left ventricular ejection fraction	≤ 100
176	Total modified Rodnan Skin Score	≤ 51
216	Highest percentage of neutrophils present in segments tested	≤ 100

(cont.)

Validation Range (continued)

Systemic Lupus Erythematosus (SLE) Pre-HSCT Data (Form 2045)		
Question	Description	Validation Range
26	Total activity index score	≤ 24
35	Total chronicity index score	≤ 12
119	Total SLEDAI score	≤ 105
200	Total SLEDAI score	≤ 105

Post-HSCT Disease Forms		
Myelodysplasia/Myeloproliferative Disorders (MDS/MPS) Post-HSCT Data (Form 2114)		
7	Blasts in marrow	0-100
Aplastic Anemia (APL) Post-HSCT Data (Form 2128)		
5	Reticulocyte level	0-90
Fanconi Anemia/Constitutional Anemia (FA/CA) Post-HSCT Data (Form 2129)		
5	Reticulocyte level	0-90
Congenital Amegakaryocytic Thrombocytopenia (CAT) Post-HSCT Data (Form 2135)		
8	Level of blasts in marrow:	0-100
Mucopolysaccharidosis and Other Storage Diseases (MUC) Post-HSCT Data (Form 2138)		
3	Recipient's enzyme activity level	< 2
66	Oxygen saturation on room air	< 100
Systemic Sclerosis (SSC) Post-HSCT Data (Form 2144)		
78	Total modified Rodnan Skin Score	0-≤ 51